Results 101 to 110 of about 39,514 (227)

Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1331-1339, May 2026.
Major depressive disorder is a highly prevalent psychological disorder worldwide and its main treatment is the use of Selective Serotonin Reuptake Inhibitors. However, few studies have demonstrated the relationship between the presence of genetic variants in pharmacogenes and the efficacy of these drugs, especially in populations with a unique genetic ...
Kaio Evandro Cardoso Aguiar, Natasha Monte da Silva, Juliana Carla Gomes Rodrigues, André Maurício Ribeiro‐dos‐Santos, Sandro José de Souza, Ândrea Ribeiro‐dos‐Santos, João Farias Guerreiro, Sidney Emanuel Batista dos Santos, Marianne Rodrigues Fernandes, Ney Pereira Carneiro dos Santos   +9 more
wiley   +1 more source

Antidepressants inhibit P2X₄ receptor function: a possible involvement in neuropathic pain relief

Molecular Pain, 2009
Background Neuropathic pain is characterized by pain hypersensitivity to innocuous stimuli (tactile allodynia) that is nearly always resistant to known treatments such as non-steroidal anti-inflammatory drugs or even opioids.
Tozaki-Saitoh Hidetoshi, Tsuda Makoto, Yamashita Tomohiro, Imai Toshiyasu, Nagata Kenichiro, Inoue Kazuhide   +5 more
doaj   +1 more source

Actionable Pharmacogenomics and Essential Medicines: An Analysis of WHO and African Lists for Safer and Efficacious Drug Use

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1371-1381, May 2026.
The World Health Organization Model Essential Medicines List and African national essential medicines lists (EMLs) detail drugs intended to be consistently available within national health systems, thereby supporting clinicians and pharmacists in making evidence‐based treatment decisions.
Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Janine Scholefield, Collen Masimirembwa   +5 more
wiley   +1 more source

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1382-1390, May 2026.
Genetic variation has a significant impact on patients' response to medicines. Variations in important pharmacogenes have been evaluated in several studies and consequently led to international guidelines from clinical pharmacogenomics consortia. However, there are limited examples of these being implemented across the African continent despite the ...
Janine Scholefield, Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Collen Masimirembwa   +5 more
wiley   +1 more source

FIGO best practice recommendations for the mental health of women at menopausal age

International Journal of Gynecology &Obstetrics, Volume 173, Issue 2, Page 588-601, May 2026.
Abstract Mental health during the menopausal transition requires focused attention to ensure supportive experiences for women. This review presents the International Federation of Gynecology and Obstetrics (FIGO) recommendations and summarizes the evidence, addressing 13 key questions framed by members of the FIGO Committee on Women at Menopausal Age ...
Suvarna Khadilkar, Hema Divakar, Chiara Benedetto, Andrea Genazzani, Diana Ramos, Elizabete Argale, Gandhali Deshpande, Martha Hicky, Agnaldo Lopes Da Silva Filho, Enrique Herrera, Milan Balkrishnan   +10 more
wiley   +1 more source

Exploratory Evaluation of Solanidine as an Endogenous Marker for CYP2D6‐Mediated Drug–Drug–Gene Interactions of Venlafaxine in Koreans

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT CYP2D6‐mediated drug–drug–gene interactions (DDGIs) are known to influence the pharmacokinetics of venlafaxine and its metabolism to O‐desmethylvenlafaxine. Solanidine and 3,4‐seco‐solanidine‐3,4‐dioic acid (SSDA) have recently been investigated as candidate endogenous CYP2D6 biomarkers; however, they remain unexplored in East Asian ...
Sungyeun Bae, Ga‐Yeong Lee, Eunsol Yang, Woori Chae, Kyung‐Sang Yu, Joo‐Youn Cho, Anhye Kim, Namyi Gu, SeungHwan Lee   +8 more
wiley   +1 more source

Treatment Outcome of Surgical Protocols for Peri‐Implantitis: A Retrospective Cohort Study in a Specialised University Centre

Journal of Clinical Periodontology, Volume 53, Issue 5, Page 658-680, May 2026.
ABSTRACT Aim To explore the treatment outcome of surgical peri‐implantitis protocols in a university‐based setting. Materials and Methods Four‐hundred and six implants in 223 patients were surgically treated by four trained surgeons using open‐flap debridement (OFD, 37 implants), implantoplasty (Impl, 39 implants), reconstructive surgery (Rec, 241 ...
Wenjie Zhou, Ausra Ramanauskaite, Clemens Raabe, Emilio A. Cafferata, Neelam Lingwal, Frank Schwarz   +5 more
wiley   +1 more source

Specific Pharmacological Effects of Paroxetine Comprise Psychological but Not Somatic Symptoms of Depression.

PLoS ONE, 2016
BackgroundMeta-analyses of placebo-controlled trials of SSRIs suggest that only a small portion of the observable change in depression may be attributed to "true" pharmacological effects.
Benjamin D Schalet, Tony Z Tang, Robert J DeRubeis, Steven D Hollon, Jay D Amsterdam, Richard C Shelton   +5 more
doaj   +1 more source

Oncosexology: A Narrative Review on Sexual Health and Quality of Life in Cancer Patients

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer remains a major global public health problem. A key aspect of cancer care among survivors is sexual health. Cancer patients experience a range of sexual dysfunctions, including erectile dysfunction, vaginal dryness, dyspareunia, and reduced libido.
Pasquale Marino, Roberta Colangelo, Paola Amendola, Ilaria Bochicchio, Alessandro Rocco Lettini, Stefania Lapadula, Alda Giuliano, Martina Catalano, Francesca Sanseverino   +8 more
wiley   +1 more source

The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.

PLoS ONE, 2014
IntroductionThe efficacy of treatment with selective serotonin reuptake inhibitors in patients with major depressive disorder (MDD) can differ depending on the patient's serotonin transporter-linked polymorphic region (5-HTTLPR) genotype, and the effects
Tetsu Tomita, Norio Yasui-Furukori, Taku Nakagami, Shoko Tsuchimine, Masamichi Ishioka, Ayako Kaneda, Norio Sugawara, Sunao Kaneko   +7 more
doaj   +1 more source